Diabetes, Metabolic Syndrome and Obesity (Jan 2023)

Adiponectin Paradox More Evident in Non-Obese Than in Obese Patients with Diabetic Microvascular Complications

  • Satoh K,
  • Nagasawa K,
  • Takebe N,
  • Kinno H,
  • Shozushima M,
  • Onodera K,
  • Oda T,
  • Hasegawa Y,
  • Satoh J,
  • Ishigaki Y

Journal volume & issue
Vol. Volume 16
pp. 201 – 212

Abstract

Read online

Ken Satoh,1 Kan Nagasawa,1 Noriko Takebe,1 Hirofumi Kinno,1 Masaharu Shozushima,1 Ken Onodera,1 Tomoyasu Oda,1 Yutaka Hasegawa,1 Jo Satoh,2 Yasushi Ishigaki1 1Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Iwate Medical University, Yahaba, Japan; 2Department of Diabetes, Tohoku Medical and Pharmaceutical University, Wakabayashi Hospital, Sendai, JapanCorrespondence: Yasushi Ishigaki, Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Iwate Medical University, 2-1-1 Idai-Dori, Yahaba, Iwate, 028-3695, Japan, Tel +81 19 613 7111, Fax +81 19 907 8270, Email [email protected]/Introduction: Adiponectin is generally regarded as a beneficial molecule, protecting against insulin resistance and atherosclerosis, and its serum levels are low in individuals with obesity as well as in those with type 2 diabetes (T2DM). However, several clinical studies have shown associations between high adiponectin values and major health concerns. These conflicting findings are termed the “adiponectin paradox”. Similarly, these paradoxical adiponectin elevations were observed in patients with diabetic microvascular complications. This cross-sectional study aimed to identify differences in factors, including adiponectin, related to diabetic vascular complications between non-obese and obese patients.Materials and Methods: Study patients with T2DM were non-obese (n=197) or obese (n=197), matched by a propensity score model adjusted with age and gender. Independent factors for each of the microvascular complications were determined using multivariate logistic regression analyses.Results: The prevalence of nephropathy was high in obese T2DM patients. In addition to long diabetes duration, elevated adiponectin was a common characteristic of patients with microvascular complications. Logistic regression analyses for microvascular complications revealed adiponectin to be highly related to retinopathy (odds ratio [OR], 1.138; 95%confidence intervals [CI], 1.004– 1.289, p< 0.001), nephropathy (OR, 1.192; CI, 1.077– 1.319, p< 0.001) and neuropathy (OR, 1.217; CI, 1.071– 1.384, p< 0.001), in non-obese patients. In contrast, the association between adiponectin values and complications was modest in obese patients.Conclusion: Adiponectin regulation in response to vascular damage differed between non-obese and obese patients, suggesting that adiponectin regulation is compromised by fat accumulation. Assuming that paradoxical elevation of adiponectin in vascular damage is a compensatory response, we speculate that responsive upregulation might be insufficient in obese patients. These newly-recognized differences in adiponectin values might lead to novel insights into adiponectin regulation and our understanding of the adiponectin paradox.Keywords: diabetic complications, obesity, adiponectin

Keywords